CTOs on the Move


 
SSPCC, Inc. is a Phoenixville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sspcc.com
  • 21 Pin Oak Dr
    Phoenixville, PA USA 19460
  • Phone: 610.933.9689

Executives

Name Title Contact Details

Similar Companies

Elite Pharmaceuticals

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite`s strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite`s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product.

Bridge Laboratories

Bridge Laboratories is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synergy Health Partners

Synergy Health Partners is the car accident doctor you can trust. We offer chiropractic treatment, physical therapy, and massages.

Sirnaomics

Sirnaomics, Inc. is a biopharmaceutical company discovering and developing novel targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology.

Diamedica

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company`s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.